STOCK TITAN

Rockwell Medical, Inc. to Present at H.C. Wainwright Annual Global Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Rockwell Medical, Inc. (Nasdaq: RMTI) announced that CEO Russell Ellison will present at H.C. Wainwright's Annual Global Life Sciences Conference in Miami, Florida, on May 24 at 3:30 PM ET. The company specializes in biopharmaceuticals focused on iron deficiency and anemia management, with FDA-approved therapies for hemodialysis patients. A video of the presentation will be available the following day on their website and archived for 90 days. Rockwell Medical also develops its Ferric Pyrophosphate Citrate platform for broader iron deficiency treatments.

Positive
  • None.
Negative
  • None.

WIXOM, Mich., May 23, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that Russell Ellison, M.D., M.Sc., President and Chief Executive Officer is scheduled to present at H.C. Wainwright's Annual Global Life Sciences Conference in Miami, Florida on Tuesday, May 24th at 3:30 PM ET.

A video webcast of the presentation will be available the following day in the "Investors" section of the Company's website at www.rockwellmed.com, and will be archived on the Company's website for 90 days.

About Rockwell Medical

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients' lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rockwell-medical-inc-to-present-at-hc-wainwright-annual-global-life-sciences-conference-301552591.html

SOURCE Rockwell Medical Technologies, Inc.

FAQ

When will Rockwell Medical present at the H.C. Wainwright Annual Global Life Sciences Conference?

Rockwell Medical will present on May 24 at 3:30 PM ET.

Who is the CEO of Rockwell Medical?

The CEO of Rockwell Medical is Russell Ellison.

What is the focus of Rockwell Medical's biopharmaceutical developments?

Rockwell Medical focuses on iron deficiency and anemia management.

Where can I find the video of Rockwell Medical's conference presentation?

The video will be available the next day in the 'Investors' section of Rockwell Medical's website.

What innovative technology is Rockwell Medical developing?

Rockwell Medical is developing Ferric Pyrophosphate Citrate (FPC) technology for treating iron deficiency.

Does Rockwell Medical have FDA-approved products?

Yes, Rockwell Medical has two FDA-approved therapies for patients undergoing hemodialysis.

Rockwell Medical, Inc. (DE)

NASDAQ:RMTI

RMTI Rankings

RMTI Latest News

RMTI Stock Data

74.01M
28.56M
12.33%
21.27%
2.65%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
WIXOM